Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodomethane SCHEMBL3387530 | 0.97 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL16903462 | 0.86 | USP2 (0.46) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL27936598 | 0.85 | NR1H2 (0.38) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL15749495 | 0.84 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL30075744 | 0.84 | NR1H2 (0.43) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL23580046 | 0.83 | NR1H2 (0.55) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL29207289 | 0.83 | USP2 (0.41) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL27743952 | 0.83 | USP2 (0.41) | NR1H2USP2SMN1; SMN2ESR2DDB1 | |
| SCHEMBL18420747 | 0.83 | RORC (0.39) | NR1H2ESR2DDB1CRBNADORA1 | |
| SCHEMBL18629582 | 0.83 | USP2 (0.42) | NR1H2USP2SMN1; SMN2ESR2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4651954-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2003104236-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
| EP-1204659-B1 | SEROTONERGIC BENZOFURANS | LILLY CO ELI (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030216568-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation,compositions and use as medicaments | WOCKHARDT LIMITED | 2003-11-20 | — | — | US | disclosed |
| WO-2003050107-A1 | NEW GENERATION TRIPLE-TARGETING, CHIRAL, BROAD-SPECTRUM ANTIMICROBIAL 7-SUBSTITUTED PIPERIDINO-QUINOLONE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION, COMPOSITIONS AND USE AS MEDICAMENTS | WOCKHARDT LIMITED (IN) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030096812-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-Quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED | 2003-05-22 | — | — | US | disclosed |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002085886-A2 | CHIRAL, BROAD-SPECTRUM ANTIBACTERIAL 7-SUBSTITUTED PIPERIDINO-QUINOLONE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS | WOCKHARDT LIMITED (IN) | 2002-10-31 | — | — | WO | disclosed |
| EP-1204659-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001009122-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | NR1H2 368/4885USP2 3092/4885SMN1; SMN2 1240/4885 |
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | NR1H2 1751/4885USP2 7/4885SMN1; SMN2 2586/4885 |
| US-20030096812-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-Quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | NR1H2 1377/4885USP2 2658/4885SMN1; SMN2 4719/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | NR1H2 1937/4885USP2 1960/4885SMN1; SMN2 2043/4885 |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | NR1H2 2682/4885USP2 1401/4885SMN1; SMN2 1138/4885 |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | NFATC1, ELANE, NCF1 | NR1H2 189/4885USP2 2542/4885SMN1; SMN2 410/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | NR1H2 883/4885USP2 3689/4885SMN1; SMN2 1015/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | NR1H2 46/4885USP2 1543/4885SMN1; SMN2 4623/4885 |
| US-20030216568-A1 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation,compositions and use as medicaments | ABCG2, CYP3A7, UGT1A7 | NR1H2 1377/4885USP2 2658/4885SMN1; SMN2 4719/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | NR1H2 2807/4885USP2 2129/4885SMN1; SMN2 4618/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | NR1H2 2591/4885USP2 55/4885SMN1; SMN2 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.